- |||||||||| dexamethasone / Generic mfg.
Journal: Immunological and hemato-biochemical effects on catfish (Clarias gariepinus) exposed to dexamethasone. (Pubmed Central) - Oct 4, 2022
After a recovery period, blood biochemical, antioxidant, and cytokine markers were still elevated compared with the control group. In conclusion, dexamethasone at concentrations present in water bodies causes deleterious effects on blood biomarkers, biochemical, and antioxidant as well as immune upregulation in catfish until after depuration period.
- |||||||||| Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
Establishment of the first inflammatory bowel disease in pregnancy multidisciplinary service in New South Wales () - Oct 4, 2022 - Abstract #AGW2022AGW_499;
Nineteen patients (44.2%) were prescribed 5-aminosalicylates alone, eight (18.6%) thiopurines, and 21 (48.8%) biologic therapy (antitumor necrosis factor agents, 12; ustekinumab, 6; vedolizumab, 3)...Two patients (4.7%) were prescribed oral budesonide during pregnancy... Establishment of a multidisciplinary clinic has enabled provision of IBD care in the reproductive stage of life, with the ongoing aim to minimize the impact of voluntary childlessness through the delivery of dedicated clinic sessions for preconception counseling and the negative impact of active disease on obstetric and maternal outcomes.
- |||||||||| Ocrevus (ocrelizumab) / Roche, Biogen
Ocrelizumab-induced medically refractory fulminant colitis requiring colectomy () - Oct 4, 2022 - Abstract #AGW2022AGW_477;
Unique to our case, the patient had a strong history of autoimmune disease, with MS and celiac disease, as well as a first-degree relative with UC. Ocrelizumab is commonly used for lymphoma, yet our search did not identify any cases of colitis reported in that population, with all identified cases occurring in patients with MS.
- |||||||||| Metastatic Crohn's disease: A treat-to-target approach and review of the literature () - Oct 4, 2022 - Abstract #AGW2022AGW_468;
We describe a patient successfully treated with combination dose-escalated infliximab, azathioprine, and topical betamethasone. This case illustrates the importance of optimizing adherence and a treat-to-target response with frequent reassessments in treatment-refractory cases.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Development of symptomatic hyponatremia due to salt-losing nephropathy from ciclosporin A used for acute severe ulcerative colitis () - Oct 4, 2022 - Abstract #AGW2022AGW_455;
The use of CsA for ASUC can cause several serum electrolyte abnormalities; however, hyponatremia is uncommon, and the mechanism can be difficult to identify and manage. If a salt-losing nephropathy is suspected, given it is usually reversible and dose dependent, a reduction in the CsA dose to target a lower trough level, if the patient's colitis is well controlled, and use of oral sodium replacement appear to be pragmatic solutions.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
COVID-19 vaccine-related liver injury: A possible emerging association () - Oct 4, 2022 - Abstract #AGW2022AGW_399;
We wish to strongly emphasize that cases such as these should not be a deterrent to COVID-19 vaccination, and infection with SARS-CoV-2 itself has been linked to the development of hepatitis. Rather, these cases add to a slowly mounting body of evidence for a possible association, and clinicians should be mindful of this when assessing patients presenting with abnormal liver enzymes after recent COVID-19 vaccination.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab-related vanishing bile duct syndrome: A rare but important complication of immunotherapy () - Oct 4, 2022 - Abstract #AGW2022AGW_344;
While immunotherapy-related hepatitis is common (up to 10% with monotherapy and 20–30% with combination immunotherapy; median time to onset of 8–12 weeks after initiation of immunotherapy), immunotherapy-related cholangitis is rare, with 53 cases reported in the literature in a recent meta-analysis and systematic review, equating to an incidence of 0.5–0.7%. Only 9% of patients had a complete response to immunosuppressive therapy, with 70% having partial response and 21% poor response.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
Liver injury due to COVID-19 vaccination () - Oct 4, 2022 - Abstract #AGW2022AGW_334;
These case reports show that COVID-19 vaccination is a rare cause of drug-induced liver injury, with varying patterns of liver function derangement. This highlights the importance of obtaining an accurate vaccination history in the evaluation of patients with deranged LFT results to establish the diagnosis.
- |||||||||| prednisolone / Generic mfg., budesonide / Generic mfg.
Esophageal stricture prophylaxis following extensive endoscopic resection () - Oct 4, 2022 - Abstract #AGW2022AGW_293;
Stricture prophylaxis in this group does not prevent strictures from forming but likely decreases their severity and avoids unplanned presentations with dysphagia. This study highlights the importance of stricture prophylaxis and the need for additional studies to improve the efficacy of available treatments.
- |||||||||| dexamethasone / Generic mfg.
Journal: Development of a physiomimetic model of acute respiratory distress syndrome by using ECM hydrogels and organ-on-a-chip devices. (Pubmed Central) - Oct 4, 2022
Having simulated the inflamed breathing lung environment, we assessed the effect of an anti-inflammatory drug (i.e., dexamethasone) by studying the secretion of the most relevant inflammatory cytokines...Further, from the individual analysis of the different stimuli, it was observed that the use of extracellular matrix hydrogels obtained from decellularized lungs had the most significant impact on the change of the inflammatory response. The developed model then opens the door for further in vitro studies with a better-adjusted response to the inflammatory hit and more robust results in the test of different drugs or cell therapy.
- |||||||||| dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
Journal: Glucocorticoids in a Neonatal Hyperoxic Lung Injury Model: Pulmonary and Neurotoxic effects. (Pubmed Central) - Oct 4, 2022
Mpz ended up with no more additional neuron loss or apoptosis risk by having interchangeable effects with others for the treatment of established BPD. Mpz and Hc seem safe as a rescue therapy in terms of adverse outcomes for established BPD in which lung and brain tissue is already impaired.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Kineret (anakinra) / SOBI, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
Journal: Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. (Pubmed Central) - Oct 4, 2022
Mpz and Hc seem safe as a rescue therapy in terms of adverse outcomes for established BPD in which lung and brain tissue is already impaired. COVID-19 vaccines may occasionally trigger HLH, and Anakinra may be an efficacious treatment option for this condition.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Buspirone Ameliorates Colon Inflammation in TNBS-Induced Rat Acute Colitis: The Involvement of TLR4/NF-kB Pathway. (Pubmed Central) - Oct 4, 2022
Tissue TNF-α and MPO activity were enhanced after induction of colitis in terms of biochemical variables; however, administration of dexamethasone or buspirone reduced TNF-α and MPO activity. Eventually, in an animal model of severe colitis, buspirone displayed anti-inflammatory characteristics via lowering the TLR4/NF-ĸB signaling pathway's activity in an animal model of acute colitis.
- |||||||||| dexamethasone / Generic mfg.
Journal: Impact of Staphylococcus aureus bacteremia in COVID-19 patients (Pubmed Central) - Oct 4, 2022
Our data suggest that BSA has a negative impact on the evolution of patients with COVID-19. However, further and preferably prospective studies are required to obtain solid data on the impact of BSA on coronavirus patients.
- |||||||||| Advaferon (interferon alfacon-1) / Astellas, Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Pathway Analysis of Patients with Severe Acute Respiratory Syndrome. (Pubmed Central) - Oct 4, 2022
However, further and preferably prospective studies are required to obtain solid data on the impact of BSA on coronavirus patients. An enhanced understanding of the pathways and molecular targets of SARS-CoV-1 in humans will contribute to current and future drug repurposing strategies, which are an essential tool to combat rapidly emerging health threats.
- |||||||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Journal: Utilization Patterns and Trends in the Use of Medications for Asthma in a Cohort of Colombian Patients. (Pubmed Central) - Oct 4, 2022
12.5% of patients (n = 495) received triple therapy (ICS/LABA + LAMA [long-acting antimuscarinic]), particularly fluticasone/salmeterol + tiotropium. The identification of treatment patterns will allow physicians and decision makers to implement strategies in order to promote adherence to treatment and improve asthma medication use.
- |||||||||| dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date: Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy (clinicaltrials.gov) - Oct 4, 2022
P3, N=60, Recruiting,
This study showed the effectiveness of pentoxifylline as an adjunct in the routine management of oral submucous fibrosis. Trial completion date: Mar 2022 --> Aug 2023 | Trial primary completion date: Feb 2022 --> May 2023
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Enrollment change, Trial termination: Steroids in Total Knee Arthroplasty (clinicaltrials.gov) - Oct 4, 2022
P4, N=1, Terminated,
Trial completion date: Mar 2022 --> Aug 2023 | Trial primary completion date: Feb 2022 --> May 2023 N=150 --> 1 | Suspended --> Terminated; Terminated after considerable time in suspended state due to inadequate staffing, the COVID pandemic, and the Responsible Party leaving Emory in August 2022.
- |||||||||| Journal: New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia. (Pubmed Central) - Oct 3, 2022
Such novel agents targeting the several immunopathological mechanisms acting in wAIHA and their possible combination, will increase the therapeutic armamentarium and possibly fill the gap of wAIHA relapsed after/refractory to rituximab. Moreover, these new target therapies may represent a tool for the unmet need of very acute cases.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Trial completion date, Trial primary completion date: Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Oct 3, 2022
P2, N=32, Recruiting,
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- |||||||||| hydrocortisone / Generic mfg.
Journal: Leukocyte Telomere Length in Children with Congenital Adrenal Hyperplasia. (Pubmed Central) - Oct 2, 2022
LTL is shorter in patients with classic than non-classic CAH, as well as those who are overtreated with hydrocortisone or treated with long-acting glucocorticoids. These findings may be attributed to chronic exposure to supraphysiologic glucocorticoid concentrations, and indicate that LTL may be used as a biomarker for monitoring glucocorticoid treatment.
- |||||||||| vilanterol (GW642444H) / GSK, Veramyst (fluticasone furoate nasal spray) / GSK
Review, Journal: May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide? (Pubmed Central) - Oct 1, 2022
We are aware of the differences between formoterol (FORM) and the not rapid acting LABAs such as e.g. salmeterol and vilanterol but our comparisons are based on currently available combination products...Here we present an alternative mode for an ICS to reach combined efficacy and safety, based on a poorly investigated and exploited physiological mechanism. A preference of this mode is broader versatility, due to that its straighter dose-response should allow a better adaptation to disease fluctuations, and that its rapid activity enables use as "anti-inflammatory reliever".
|
